Value of serum tumor markers for predicting EGFR mutations in non-small cell lung cancer patients

2020 ◽  
Vol 49 ◽  
pp. 151633
Author(s):  
Linfang Wen ◽  
Shenghao Wang ◽  
Weiran Xu ◽  
Xiaofeng Xu ◽  
Mei Li ◽  
...  
Lung Cancer ◽  
2007 ◽  
Vol 57 (2) ◽  
pp. 213-221 ◽  
Author(s):  
Chao-Hua Chiu ◽  
Yu-Ning Shih ◽  
Chun-Ming Tsai ◽  
Jia-Ling Liou ◽  
Yuh-Min Chen ◽  
...  

2013 ◽  
Vol 8 (3) ◽  
pp. 295-300 ◽  
Author(s):  
Niki Karachaliou ◽  
Carlota Costa ◽  
Ana Gimenez-Capitan ◽  
Miguel Angel Molina-Vila ◽  
Jordi Bertran-Alamillo ◽  
...  

PLoS ONE ◽  
2016 ◽  
Vol 11 (12) ◽  
pp. e0168795 ◽  
Author(s):  
Wen-E Wei ◽  
Nai-Quan Mao ◽  
Shu-Fang Ning ◽  
Ji-Lin Li ◽  
Hai-Zhou Liu ◽  
...  

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 17126-17126
Author(s):  
W. Dong ◽  
X. Ren ◽  
P. Liu

17126 Background: To investigate the correlation of C-reactive protein (CRP) and tumor markers such as carcinoembryonic antigen (CEA), CA125, cytokeratin 19 antibody (Cyfra 21–1) in non-small cell lung cancer (NSCLC) patients. Methods: CRP, CEA, CA125, Cyfra 21–1 were measured in the serum of 79 patients with advanced non-small cell lung cancer (stage III and IV ) by independent samples t test. Results: It showed statistically significant difference (P < 0.05) in the level of CRP, CEA, CA125, Cyfra211 between lung cancer patients (25.21 ± 19.12 mg/L, 62.89 ± 53.96 ng/L, 46.36 ± 30.03 U/L, 6.85 ± 2.42 ng/L, respectively) and the control subjects. CRP, CA125 showed no significant difference between squamous carcinoma and adenocarcinoma (P = 0.832, 0.406, respectively). CEA was higher in adenocarcinoma than in squamous carcinoma (P = 0.002). Cyfra211 was lower in adenocarcinoma than in squamous carcinoma (P = 0.039). The increase of CRP was accompanied with the increase of CEA, CA125 and Cyfra211 (p < 0.05). At the same time, CRP elevated while CEA, CA125, Cyfra211 increased (p < 0.05). Conclusions: All of CRP, CEA, CA125 and Cyfra211 increased in advanced non-small lung cancer. Combined monitoring on CRP with CEA, CA125, Cyfra211 may be a complementary method in advanced non-small cell lung cancer patients. No significant financial relationships to disclose.


2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e19111-e19111
Author(s):  
Radmila Jankovic ◽  
Milena Cavic ◽  
Jelena Spasic ◽  
Ana Krivokuca ◽  
Ksenija Brotto ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document